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Objectives The purpose of this study was to investigate the safety, tolerability, and efficacy of RVX-208, the first oral agent
designed to enhance apolipoprotein (apo) A-I synthesis.
Background No agent that selectively induces synthesis of apoA-I has reached an advanced stage of clinical development.
Methods A total of 299 statin-treated patients with coronary artery disease were treated with placebo or with RVX-208 at
a dose of 50, 100, or 150 mg twice daily for 12 weeks. Changes in lipid-related biomarkers, in addition to safety
and tolerability, of RVX-208 were investigated.
Results For each dose of RVX-208, individual pairwise comparisons of apoA-I changes with placebo, the primary end
point, did not achieve statistical significance. However, treatment with RVX-208 was associated with a dose-
dependent increase in apoA-I levels by up to 5.6% (p  0.035 for trend). Administration of RVX-208 resulted in
significant increases in levels of high-density lipoprotein cholesterol (HDL-C) ranging from 3.2% to 8.3% (p 
0.02), and large HDL particles increased by 11.1% to 21.1% (p  0.003). ApoA-I levels increased rapidly from
8 to 12 weeks, suggesting that peak pharmacological effect has not been achieved by the end of the 12-week
study. Transient and reversible elevations in liver transaminases 3 times the upper limit of normal were ob-
served in 18 patients treated with RVX-208, with no associated increase in bilirubin levels.
Conclusions Administration of RVX-208 for 12 weeks was associated with increases in apoA-I, HDL-C, and concentration of large
HDL particles, consistent with facilitation of cholesterol mobilization. Maximal increases in apoA-I may require longer
exposure. An increase in liver enzymes was observed with active treatment. (Clinical Trial for Dose Finding and Safety
of RVX000222 in Subjects With Stable Coronary Artery Disease; NCT01058018) (J Am Coll Cardiol 2011;57:
1111–9) © 2011 by the American College of Cardiology Foundation
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ApoA-I Induction in CAD Patients March 1, 2011:1111–9Despite the widespread imple-
mentation of low-density lipo-
protein cholesterol (LDL-C)
lowering strategies, there remains
significant residual risk of adverse
cardiovascular events in developed
countries (1). Accordingly, there
exists an ongoing need to develop
additional therapeutic approaches
to achieve more effective reduc-
tions in cardiovascular risk.
For several decades, approaches
that increase the levels of high-
density lipoprotein cholesterol
(HDL-C) have represented an at-
tractive target for the development of novel cardioprotective
therapies. This strategy approach is based upon observations
from population (2) and animal (3,4) studies suggesting that
levels of HDL-C are inversely correlated with the risk of
cardiovascular morbidity and mortality. The finding that infu-
sions of lipid-poor HDL subfractions promote rapid regression
of coronary atherosclerosis further supports the concept that
enhancing the biological activity of HDL is beneficial in
humans (5–7).
See page 1120
Although interest has focused primarily on therapies
designed to elevate serum levels of HDL-C, an alternative
approach involves up-regulation of endogenous synthesis of
apolipoprotein (apo) A-I, the major protein carried on
HDL particles. The theoretical advantages of enhancing
apoA-I synthesis stem from the ability of this protein to
generate new HDL particles, which act as the vehicle for
promotion of reverse cholesterol transport (RCT). HDL
particles also exert favorable effects on inflammatory, oxida-
tive, apoptotic, endothelial, and thrombotic pathways,
which may contribute to a beneficial effect on atheroscle-
rotic disease (8).
RVX-208 is the first oral agent to reach clinical develop-
ment that selectively induces hepatic synthesis of apoA-I.
Mechanistic studies demonstrated that RVX-208 enhances
apoA-I transcription in hepatic cell lines and does not
appear to modulate peroxisome proliferator-activated recep-
tor (PPAR), liver X receptor (LXR), or cholesteryl ester
transfer protein (CETP) mediated pathways (Johansson J,
unpublished data, September 2010). In preclinical studies,
administration of RVX-208 to nonhuman primates resulted
in a sustained increase in circulating levels of pre1-HDL,
the lipid-deplete form of HDL, and 1-HDL, the fully
mature particle. These changes produced an increase in
systemic capacity to promote cholesterol efflux in ex vivo
assays (9). Similar findings have been reported with short-
term treatment in healthy volunteers (9). The ASSERT
Abbreviations
and Acronyms
2D  2-dimensional
apo  apolipoprotein
bid  twice daily
HDL-C  high-density
lipoprotein cholesterol
IQR  interquartile range
ITT  intent to treat
LDL-C  low-density
lipoprotein cholesterol
RCT  reverse cholesterol
transport(ApoA-I Synthesis Stimulation Evaluation in Patients Re-quiring Treatment for Coronary Artery Disease) study
assessed the safety, tolerability, and efficacy of RVX-208 at
varying doses in patients with stable coronary artery disease,
who were on statin therapy. This report represents the first
published description of the potential lipid-related benefits,
tolerability, and safety of a novel oral agent that stimulates
endogenous production of apoA-I in patients with estab-
lished coronary artery disease.
Methods
Study design. The trial was a multicenter, randomized,
double-blind, placebo-controlled study performed at 35
sites in the U.S. A central institutional review board
(Sterling, Atlanta, Georgia) approved the protocol, and all
patients provided written informed consent. The study was
appropriately registered on clinicaltrials.gov following com-
mencement of patient enrollment.
Patients of at least 18 years of age were required to have
documented coronary artery disease on the basis of coronary
angiography or previous coronary revascularization or myo-
cardial infarction, with no clinical event within the 90 days
prior to randomization. All patients were treated with a
statin, with no change in dose for at least 30 days prior to
randomization. Investigators were instructed not to adjust
statin dosages during the trial. Patients were excluded for
severe heart failure, uncontrolled hypertension, evidence of
hepatic or renal impairment, or the presence of a triglyceride
level 400 mg/dl. Treatment with any fibric acid derivative
or niacin at a dose 250 mg daily was not permitted within
the 90 days prior to randomization and for the duration of
the study. All patients entered an active-treatment phase for
12 weeks, during which they were randomized in a 1:1:1:1
fashion to treatment with RVX-208 at a dose of 50, 100, or
150 mg or with matching placebo twice daily (bid).
Clinic visits and laboratory tests. Patients were examined
during scheduled clinic visits every 2 weeks during the treat-
ment phase and a follow-up visit 4 weeks following cessation of
the study drug (Fig. 1). A central laboratory performed all
biochemical determinations (Icon, Farmingdale, New York).
Levels of apoA-I were determined by turbidometric immuno-
assay (Wako Chemicals, Richmond, Virginia) and HDL
subclasses characterized by 2-dimensional (2D) nondenaturing
gel electrophoresis, immunoblotting, and image analysis (Bos-
ton Heart Labs, Boston, Massachusetts) as previously de-
scribed (10). Image quantification was determined by the
percentage distribution of each HDL subclass within the total
HDL pool. Absolute concentrations were calculated by mul-
tiplying the plasma apoA-I concentration (mg/dl) by the
percentile value of each HDL subclass. Measurements of
lipoprotein particle number and size were performed by nuclear
magnetic resonance (LipoScience, Raleigh, North Carolina) as
previously described (11). Particle concentrations of lipoprotein
subclasses of different sizes were calculated from the measured
amplitudes of their spectroscopically distinct lipid methyl
signals. Lipoprotein levels and safety laboratory measurements
C
t
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March 1, 2011:1111–9 ApoA-I Induction in CAD Patientswere obtained and the occurrence of any adverse reactions
recorded at each study visit.
Statistical tests. The primary end point was the percentage
change in plasma apoA-I levels from baseline to 12 weeks
post-randomization for each treatment arm compared with
placebo. A sample size of 64 patients per group was selected
to provide 80% power to detect an 8% increase in apoA-I,
assuming an SD of 15% for the comparison of each dose of
RVX-208 to placebo with a 5% type I error rate (1-sided
test). With an anticipated dropout rate of approximately
10%, enrollment of 280 patients was calculated to provide
an adequate number of evaluable patients.
Demographic and laboratory characteristics are summa-
rized for all randomized patients taking at least 1 dose of
study drug using an intent-to-treat (ITT) approach. The
analysis of safety was performed in all ITT patients through
4 weeks post-treatment. Categorical variables are described
using frequencies, whereas continuous variables are reported
as mean and SD, median and interquartile range (IQR), or
geometric mean, as appropriate. The efficacy analyses were
performed on patients in the ITT population with both a
baseline and at least 1 post-baseline value through the
12-week treatment period. A last observation carried for-
ward methodology was used when the 12-week value was
not available. A nonparametric rank analysis of covariance
(ANCOVA) was employed to compare percentage change
Figure 1 Flow of Patients Over the 18-Week Course of the ASS
The study consisted of: 1) a 2-week screening phase; 2) a 12-week treatment pha
ASSERT  ApoA-I Synthesis Stimulation Evaluation in Patients Requiring Treatmenfrom baseline between each active treatment group and wplacebo after controlling for the ranked baseline value. p
Values were calculated for overall trend and for comparisons
with placebo, with the pairwise p values adjusted according
to the Dunnett method. If the overall p value was 0.05,
pairwise comparisons were considered significant if0.025.
For the HDL subclass data, an ANCOVA analysis was
performed following a log-transformation of the ratio of
follow-up to baseline as the dependent variable and the log
of baseline as a covariate. Ad hoc Spearman correlation
coefficients were generated to evaluate relationships between
changes in select lipid parameters. Analyses were performed
using SAS statistical software (version 8.2, SAS Institute
Inc., Cary, North Carolina). An independent statistician
(K.W.) received the entire raw dataset, reviewed the analytic
plan for appropriateness and accuracy, and confirmed all of
the analyses.
Results
Participants. Between December 16, 2009, and February 2,
2010, 360 patients were enrolled in the study, of which 299
subjects were ultimately randomized to a treatment group.
The disposition of these patients is shown in Figure 2. The
baseline characteristics of the patients are shown in Table 1.
haracteristics were similar for all treatment groups and are
herefore presented in a summary fashion. The mean age
Study
d 3) a 4-week post-treatment phase.
oronary Artery Disease; bid  twice daily.ERT
se; an
t for Cas 66 years, 75% were male, and 93% were Caucasian.
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ApoA-I Induction in CAD Patients March 1, 2011:1111–9Consistent with a population of patients with established
coronary artery disease, there was a high prevalence of
obesity, with a mean body mass index 30 kg/m2, and with
major cardiovascular risk factors. In association with uni-
versal use of statins, levels of LDL-C and triglycerides were
consistent with contemporary treatment goals at 81 mg/dl
and 115 mg/dl, respectively. In addition, average levels of
HDL-C and apoA-I were within normal limits, averaging
46 and 141 mg/dl, respectively. Approximately 42% of
patients had low levels of HDL-C (40 mg/dl in males,
50 mg/dl in females).
Effects on conventional lipid parameters. Table 2 sum-
marizes the percentage change from baseline in measures
of conventional lipid parameters. Compared with pla-
cebo, the effect of each dose of RVX-208 on apoA-I, the
primary end point of the study, did not achieve statistical
significance. However, a dose-dependent increase in
levels of apoA-I, by up to 5.6% (p  0.035 for overall
trend) was observed across all treatment groups. Signifi-
cant increases were observed in levels of HDL-C by 3.2% to
8.3% (p  0.02 for overall trend) with increasing doses of
RVX-208. The majority of the increase in HDL-C levels
appeared to occur between weeks 8 and 12 of the treatment
period, with no evidence of a plateau in this effect (Fig. 3). No
changes in levels of atherogenic lipid parameters were observed
Figure 2 Disposition of Patients Over the 18-Week Course of t
Major reasons for screen failure and discontinuation from the study are summarizat any dose of RVX-208. 1Effects on lipoprotein particle parameters. Table 3 sum-
marizes the percentage change from baseline in lipoprotein
particle measures, determined by nuclear magnetic reso-
nance spectroscopy analysis. Administration of RVX-208
was associated with a significant increase in mean size of
circulating HDL particles by 1.1% to 1.2% (p  0.001 for
overall trend). This appeared to be predominantly associated
with significant increases in the concentration of large HDL
particles by 11.1% to 21.1% (p  0.003 for trend). More
pronounced effects were observed at the 2 highest doses of
RVX-208. Although a trend towards dose-dependent re-
duction in levels of small HDL particles was observed, this
just failed to reach conventional levels of statistical signifi-
cance (p  0.07 for trend). No change in the total number
of circulating HDL particles was observed in association
with administration of RVX-208. Similarly, RVX-208
treatment was not associated with significant changes in the
number or size of LDL particles in the systemic circulation.
HDL subclass distribution was also characterized by 2D gel
electrophoresis. Compared with placebo, RVX-208 adminis-
tration was not associated with any significant change in the
concentration of lipid-deplete forms of HDL with pre1
mobility. In contrast, an increase in concentration of larger
1-HDL particles was observed in association with treatment
with RVX-208 at the 100 mg bid (8.0% [IQR: 0.7 to
17.5], p  0.046) and 150 mg bid (8.8% [IQR: 0.2 to
SERT Study
breviations as in Figure 1.he AS
ed. Ab8.6], p  0.03) dosages. This is consistent with the increase
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March 1, 2011:1111–9 ApoA-I Induction in CAD Patientsin large HDL particles observed in the nuclear magnetic
resonance analysis.
Significant correlations in the combined RVX-208 dos-
age groups were observed between changes in apoA-I and
changes in HDL-C (r  0.70, p  0.001), pre1-HDL
r  0.30, p  0.001), and 1-HDL (r  0.57, p  0.001).
Similar relationships were noted between changes in levels
of HDL-C and HDL subclasses. No significant relation-
ship was observed between changes in pre1 and 1 forms
f HDL (r  0.07, p  0.31), which may reflect the
bility of a given HDL particle to continue to accumulate
holesterol with ongoing lipid mobilization.
afety assessment. Laboratory measures of drug safety are
ummarized in Table 4 and Figure 4. A dose-dependent
ncrease in liver transaminase levels, peaking at week 8, was
bserved. Elevations of liver transaminases 3 times the
Baseline Demographics and Biochemical ParametersTable 1 Baseline Demographics and Biochemical Parameters
Parameter
Cohort
(n  299)
Placebo
(n  74)
Age, yrs 65.8 9.7 66.8 9.7
Male 225 (75.3) 54 (73.0)
Caucasian 279 (93.3) 70 (94.6)
Body mass index, kg/m2 30.7 5.9 31.3 6.0
Hypertension 262 (87.6) 64 (86.5)
Diabetes 88 (29.4) 20 (27.0)
Smoker 51 (17.1) 10 (13.5)
Statin use
Atorvastatin 75 (25.1) 18 (24.3)
Rosuvastatin 68 (22.7) 16 (21.6)
Simvastatin 123 (41.1) 28 (37.8)
Other 33 (11.1) 12 (16.2)
Total cholesterol, mg/dl 150 (131–171) 150 (129–177
LDL-C, mg/dl 76 (66–93) 75 (63–97)
HDL-C, mg/dl 44 (37–53) 47 (39–53)
Triglycerides, mg/dl 115 (86–157) 121 (87–163)
Non–HDL-C, mg/dl 101 (87–124) 99 (84–127)
Apolipoprotein B, mg/dl 76 (65–90) 76 (64–92)
Apolipoprotein A-I, mg/dl 141 (123–161) 145 (124–166
hsCRP, mg/l 1.8 (0.8–4.2) 1.7 (0.8–4.1)
Values are reported as mean  SD, n (%), or median (interquartile range).
bid  twice daily; HDL-C  high-density lipoprotein cholesterol; hsCRP  high-sensitivity C-reac
Percentage Changes in Conventional Lipid and Inflammatory ParamTable 2 Percentage Changes in Conventional Lipid and Inflam
Parameter
Placebo
(n  74)
RVX-208 50 mg
(n  76)
Apolipoprotein A-I, mg/dl 0.9 (5.7 to 7.6) 0.1 (4.0 to 7.
HDL-C, mg/dl 0 (6.1 to 8.8) 3.2 (1.9 to 10
LDL-C, mg/dl 4.2 (8.5 to 15.0) 0.7 (8.6 to 8.
Triglycerides, mg/dl† 1.6 (15.8 to 25.3) 2.2 (14.0 to 2
Total cholesterol, mg/dl 1.6 (6.1 to 10.7) 0.7 (4.9 to 9.
Non-HDL-C, mg/dl 1.8 (6.5 to 12.7) 0 (6.2 to 9.
Apolipoprotein B, mg/dl 3.8 (12.7 to 7.2) 6.6 (17.4 to 1
hsCRP, mg/l† 2.5 (33.3 to 45.2) 13.0 (40.8 to 2
Values are reported as median (interquartile range) or percentage change in conventional lipid and
daily, except as noted. p values were generated from a model adjusting for baseline values. *p  0.01 c
Abbreviations as in Table 1.pper limit of normal were observed in patients treated with
VX-208 (n  18, p  0.009 for trend), with a greater
ncidence in patients receiving either 100 or 150 mg twice
aily, with elevations greater than eight times the upper
imit of normal in 8 of these patients. The majority of these
ubstantial elevations were observed between 4 and 8 weeks
uring the treatment period, demonstrating a pattern that
ncluded a rapid increase in levels, and return to baseline
evels within 2 weeks of drug discontinuation. One episode
ccurred during the post-treatment phase, which was sim-
larly observed to rapidly resolve. Furthermore, an additional
pisode with rapid resolution was observed in a patient who
as seropositive for hepatitis C. A greater proportion of
atients treated with high-dose statin therapy demonstrated
ubstantial transaminase elevations when treated with
VX-208 (13.3% vs. 6.7%, p  0.14), although this finding
RVX 50 mg bid
(n  76)
RVX 100 mg bid
(n  75)
RVX 150 mg bid
(n  74)
65.9 9.9 65.8 10.9 67.3 8.2
58 (76.3) 59 (78.7) 54 (73.0)
69 (90.8) 71 (94.7) 69 (93.2)
30.2 6.7 30.1 5.0 31.1 5.9
65 (85.5) 65 (86.7) 68 (91.9)
22 (28.9) 18 (24.0) 28 (37.8)
12 (15.8) 17 (22.7) 12 (16.2)
17 (22.4) 25 (33.3) 15 (20.3)
22 (28.9) 11 (14.7) 19 (25.7)
28 (36.8) 33 (44.0) 34 (45.9)
9 (11.8) 6 (8.0) 6 (8.1)
146 (133–167) 149 (133–171) 152 (131–169)
77 (65–91) 74 (67–88) 81 (67–94)
43 (36–51) 46 (37–51) 44 (36–54)
125 (84–157) 114 (88–194) 109 (89–139)
102 (90–118) 97 (90–124) 104 (86–124)
74 (65–86) 75 (65–84) 80 (65–93)
137 (117–158) 143 (126–158) 137 (122–164)
1.8 (1.0–4.1) 2.3 (0.8–4.6) 1.2 (0.6–4.1)
tein; LDL-C  low-density lipoprotein cholesterol.
y Parameters
RVX-208 100 mg bid
(n  75)
RVX-208 150 mg bid
(n  74)
Overall
p Value
3.8 (3.7 to 9.4) 5.6 (1.1 to 14.3) 0.035
6.3 (3.4 to 14.9) 8.3 (1.9 to 17.9)* 0.02
1.6 (9.4 to 15.4) 1.0 (14.2 to 10.1) 0.79
4.5 (15.5 to 26.8) 6.5 (12.7 to 26.7) 0.85
3.5 (4.1 to 14.4) 4.3 (4.7 to 12.5) 0.60
3.6 (7.0 to 12.8) 2.2 (11.2 to 15.1) 0.99
6.7 (16.4 to 4.9) 2.0 (16.3 to 4.8) 0.45
17.5 (48.1 to 24.2) 22.0 (39.5 to 28.6) 0.33
atory markers in patients treated with placebo, or RVX-208 at a dose of 50, 100, or 150 mg twice)
)etersator
bid
7)
.1)
9)
5.5)
0)
9)
.3)
7.9)
inflamm
ompared with placebo. †Values are reported as geometric mean percentage change.
c1116 Nicholls et al. JACC Vol. 57, No. 9, 2011
ApoA-I Induction in CAD Patients March 1, 2011:1111–9was not statistically significant. No episode of transaminase
elevation was accompanied by an increase in levels of
bilirubin. Similarly, increases in creatinine levels by more
than 1.5-fold greater than baseline levels were observed in 6
patients treated with 100 or 150 mg of RVX-208 twice
daily, although this did not achieve statistical significance
Figure 3 Time Course of Changes
Time course of median percentage change in high-density lipoprotein (HDL) choles
cles) or RVX-208 at a dose of 50 mg (blue squares), 100 mg (green triangles), o
parison with placebo. p values for changes in parameters were generated from a m
Baseline and Percentage Change in Nuclear Magnetic Resonance–Table 3 Baseline and Percentage Change in Nuclear Magnetic
Parameter
Placebo
(n  74)
RVX-208 5
(n 
Total HDL particles, particles/l
Baseline 32.3 (28.1 to 36.3) 31.2 (26.9 t
Percentage change 1.2 (8.4 to 8.6) 4.0 (4.7
HDL particle size, nm
Baseline 8.6 (8.4 to 9.0) 8.7 (8.4 to
Percentage change 0 (2.2 to 1.2) 1.1 (1.1
Large HDL particles, particles/l
Baseline 5.0 (3.5 to 6.9) 4.6 (3.2 to
Percentage change 0.5 (12.7 to 22.2) 11.1 (7.1
Small HDL particles, particles/l
Baseline 23.8 (21.2 to 27.5) 24.0 (20.4 t
Percentage change 2.6 (8.9 to 14.7) 0.4 (13.9
Total LDL particles, particles/l
Baseline 1,077 (841 to 1,290) 1,020 (905 t
Percentage change 3.8 (4.6 to 17.4) 3.8 (12.2
LDL particle size, nm
Baseline 20.6 (20.3 to 21.1) 20.5 (20.2 t
Percentage change 1.0 (2.1 to 0.5) 0 (1.9
Large LDL particles, particles/l
Baseline 285 (194 to 380) 238 (163 t
Percentage change 7.9 (38.9 to 20.5) 3.4 (28.1
Small LDL particles, particles/l
Baseline 770 (554 to 960) 703.5 (555 t
Percentage change 8.4 (11.2 to 30.5) 8.5 (15.2
Values are reported as the median (interquartile range) baseline and percentage change in nucle
RVX-208 at a dose of 50, 100, or 150 mg twice daily. p values for changes in parameters were
ompared with placebo.
Abbreviations as in Table 1.compared with placebo (p  0.07). Addition of RVX-208
to background statin therapy was not associated with
increases in levels of creatinine phosphokinase. One patient
treated with RVX-208 50 mg bid died, and 2 patients
treated with RVX-208 100 mg bid experienced a myocardial
infarction during the treatment period. None of these
nd number of large HDL particles in patients treated with placebo (black cir-
mg (inverted red triangles) twice daily. *p  0.01 and **p  0.001 for com-
adjusting for baseline values.
ed Lipoprotein Particle Parametersnance–Derived Lipoprotein Particle Parameters
bid RVX-208 100 mg bid
(n  75)
RVX-208 150 mg bid
(n  74)
Overall
p Value
) 32.7 (28.7 to 35.6) 29.9 (27.2 to 34.7) 0.16
) 2.8 (5.1 to 11.0) 5.1 (4.8 to 16.5) 0.80
8.7 (8.4 to 8.9) 8.7 (8.5 to 9.0) 0.50
1.2 (0 to 2.4)* 1.1 (1.1 to 2.4)* 0.001
4.8 (3.3 to 6.7) 5.3 (3.7 to 7.3) 0.74
) 20.2 (1.5 to 52.1)† 21.1 (8.8 to 50.8)* 0.003
) 24.8 (22.7 to 27.2) 22.8 (20.4 to 26.2) 0.19
) 2.6 (14.0 to 6.3) 4.0 (17.3 to 7.9) 0.07
1) 1,022 (891 to 1,152) 1,079 (848 to 1,246) 0.82
.8) 0.8 (12.7 to 16.0) 4.1 (8.5 to 19.2) 0.25
) 20.6 (20.3 to 21.1) 20.6 (20.3 to 21.2) 0.84
0.5 (1.9 to 1.5) 0.5 (2.5 to 1.5) 0.59
269 (172 to 404) 282 (187 to 400) 0.84
.6) 0.4 (35.4 to 26.3) 1.6 (28.2 to 35.7) 0.83
707 (578 to 878) 727 (538 to 934) 0.89
.4) 3.5 (16.5 to 29.8) 10.4 (11.7 to 32.7) 0.34
etic resonance spectroscopy–derived lipoprotein parameters in patients treated with placebo, or
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related to study medication. There was no difference be-
tween treatment groups with regard to the rate of investi-
gator reported adverse events.
Discussion
Considerable attention has focused on the development
of new therapeutic agents that substantially elevate levels
of HDL-C. However, development of pharmacological
therapies that raise HDL-C levels has been challenging,
in part because the underlying biology is substantially
more complex than other lipoprotein-directed therapies.
HDL circulates in many forms, including both lipid-rich
and lipid-poor subfractions (12). It appears that lipid-
poor pre1-HDL fractions acquire cholesterol from
macrophages in atherosclerotic plaques. These particles
increase in size as they accumulate cholesterol. Choles-
terol is ultimately taken up by the liver from these larger,
lipid-rich 1-HDL particles or transferred to apoB-
ontaining particles, a process known as RCT (13).
re1-HDL represents the most efficient substrate for
nhancing RCT, which is considered a pivotal mecha-
ism underlying the potential benefits of HDL-C–
Figure 4 Time Course of Alanine Transaminase Changes
Time course of median percentage change in alanine transaminase in patients
treated with placebo (black circles) or RVX-208 at a dose of 50 mg (blue
squares), 100 mg (green triangles), or 150 mg (inverted red triangles) twice
daily.
Biochemical Safety ParametersTable 4 Biochemical Safety Parameters
Parameter
Placebo
(n  74)
RVX-208 50 m
(n  76)
ALT or AST 3 ULN 0 (0) 3 (3.9)
ALT or AST 8 ULN 0 (0) 2 (2.6)
Total bilirubin 2 ULN 0 (0) 0 (0)
CK elevation 3 ULN 4 (5.4) 1 (1.3)
Creatinine elevation 1.5 baseline 0 (0) 0 (0)
Values are reported as the n (%) of subjects experiencing laboratory measures of adverse events.
ALT  alanine transaminase; AST  aspartate transaminase; bid  twice daily; CK  creatininoaising therapies (14). Because apoA-I has the capacity to
enerate more lipid-poor pre1-HDL particles, most
authorities believe that enhancing production of apoA-I
represents the most promising approach to HDL modu-
lation.
In this study, we characterized the early efficacy, tolera-
bility, and safety of a novel inducer of endogenous apoA-I
synthesis in patients with stable coronary artery disease who
received concomitant statin treatment. Although the primary
end point was not achieved, modest dose-dependent increases
in circulating levels of apoA-I, HDL-C, and the concentration
of large HDL particles were observed. The time course of the
observed changes suggests that the maximal drug effects were
not observed during this 12-week trial (Fig. 3). The increase in
large HDL particles, exceeding 20% for the highest dosage, is
consistent with the proposed mechanism of action of
RVX-208. The increase in apoA-I should theoretically
increase levels of lipid-poor pre1-HDL particles, which
ubsequently mature into lipid-rich large HDL particles by
cquiring cholesterol from macrophages in atherosclerotic
laques. Although these findings suggest that administra-
ion of RVX-208 is likely to facilitate cholesterol mobiliza-
ion, this requires further investigation.
The 2D gel electrophoresis analysis revealed an increase
n the circulating pool of larger, lipid-rich HDL particles
ith 1 mobility. Although significant correlations were
bserved between changes in levels of apoA-I and all
dditional HDL-related parameters, there was no apparent
elationship between changes in the lipid-deplete and lipid-
ich particle subclasses. Given that RVX-208 has no effect
n the activity of CETP (9), this could be consistent with
he ability of a given HDL particle to continue to promote
ipid mobilization over time. The finding that these corre-
ations are similar in both placebo and active treatment
roups suggests that the potential benefit of RVX-208 may
e exclusively related to its ability to act as a physiological
witch of the HDL synthetic process, rather than having
ny additional activity at other stages that regulate HDL
etabolism.
Although the observed changes in lipid parameters in
tatin-treated patients were modest, increases of a similar
agnitude in HDL-related parameters for other therapies,
uch as statins and fibrates, have reduced adverse clinical
RVX-208 100 mg bid
(n  75)
RVX-208 150 mg bid
(n  74)
Overall
p Value
8 (10.7) 7 (9.5) 0.009
4 (5.3) 2 (2.7) 0.28
0 (0) 0 (0) 1.00
0 (0) 3 (4.1) 0.10
3 (4.0) 3 (4.1) 0.07
phokinase; ULN  upper limit of normal.g bidutcomes and exerted a beneficial effect on the progression
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atherosclerosis was observed with infusions of lipid-deplete
forms of HDL without any increase in steady-state levels of
HDL-C (5–7). The most striking effect of RVX-208 was
elevation of the concentration of larger HDL particles.
Levels of this HDL subclass were a strong predictor of
cardiovascular protection in population studies (10,19).
Niacin, the approved therapeutic agent with the greatest
HDL-C raising also appears to promote large HDL parti-
cles, a finding that strongly associates with slowing of
coronary disease progression (20). The majority of changes
were observed between 8 and 12 weeks following initiation
of treatment, with no clear evidence of a plateau in efficacy.
Further incremental benefit may be observed during longer
duration of treatment. This would be consistent with the
experience of many other agents that raise HDL-C, that
often take many months to achieve maximal elevations
(21–23).
In general, administration of RVX-208 was well toler-
ated. However, compared with placebo, a greater number of
patients treated with RVX-208 demonstrated elevations in
transaminase levels. These increases were transient and
reversible, characterized by rapid increases in levels, typically
between weeks 4 and 8, with rapid return to baseline levels
upon discontinuation of the study drug. The mechanism
underlying this pattern remains to be fully elucidated.
However, it should be noted that increases in transaminases
are common with virtually all lipid-modulating therapies,
including statins, fibrates, and niacin (24), and more re-
cently with HDL infusions (5,6). The lack of an associated
rise in bilirubin levels suggests that there was no apparent
hepatocellular injury. However, because of the short dura-
tion of the trial and limited sample size, we cannot rule out
adverse hepatic effects during long-term administration.
Ultimately, the overall balance between efficacy and safety
must be determined in future clinical trials of longer
duration.
Recent evidence has supported the concept that the
functional quality of HDL may be a pivotal factor in
determining its ability to protect against cardiovascular
disease. Findings that patients with established coronary
artery disease, despite having very high levels of HDL-C,
often have pro-inflammatory forms of HDL suggest that
the functional activity, rather than the quantity, may be a
more important therapeutic target (25). This is further
supported by observations that relatively modest changes in
levels of HDL-C are associated with the cardiovascular
benefit of many lipid-modifying therapies (15–18), whereas
substantial HDL-C increases with the cholesteryl ester
transfer protein inhibitor, torcetrapib, were associated with
an adverse clinical outcome (21). For several decades,
up-regulating endogenous expression of apoA-I has pre-
sented an attractive option for the development of novel
antiatherosclerotic agents. Theoretically, this approach
should result in the generation of nascent HDL particles
with the capacity to perform a range of favorable biologicalfunctions. The objective of this approach is primarily to
enhance functionality, as opposed to substantially elevate
HDL-C. However, to date, identification of a compound
that selectively increases apoA-I transcription has remained
elusive. Accordingly, although the changes observed in this
study are modest, it remains to be determined whether this
will translate into any cardiovascular benefit.
One of the major challenges in the evaluation of therapies
that target HDL and its biological functions is the lack of
standardized and well-validated methods to characterize
HDL functionality in humans. Traditional measures of
apoA-I and HDL-C simply quantify the mass of protein
and cholesterol, respectively, carried within the circulating
HDL pool. Although systemic measures of these values
have been demonstrated in population studies to predict
cardiovascular risk (2,26), there is currently no evidence that
they accurately reflect the functional quality of HDL parti-
cles. As a result, there remains an urgent need to develop
additional assays that will provide complementary informa-
tion with regard to HDL quality. Although it is possible to
measure the ability of HDL function to promote cholesterol
efflux (27) and modify cellular inflammatory, oxidative, and
apoptotic pathways in ex vivo assays (25,28,29), it has not
been established to what extent these reflect in vivo activity.
Similarly, although measurement of fecal sterol excretion
has been employed as an indirect measure of RCT (30), it is
unknown to what degree this reflects a precise measurement
of lipid removal from peripheral tissues. Furthermore,
reports of a lack of benefit of elevated HDL-C levels in
recent statin trials places additional uncertainty regarding
the potential efficacy of HDL targeted therapies (26,31).
This will be resolved only in the context of large-scale
clinical trials.
Conclusions
Administration of an oral inducer of endogenous apoA-I
synthesis resulted in changes in circulating HDL particles
that may be consistent with enhanced cholesterol mobiliza-
tion, although this requires further investigation. Although
an increase in reversible elevations in liver enzymes was also
observed, the balance with cardiovascular benefit remains to
be determined in large, prospective clinical trials that will
evaluate the impact of this novel agent. Ultimately, the
ability to bring this strategy to clinical practice would
represent a significant paradigm change, in which the focus
is predominantly on specifically targeting the functional
quality, rather than quantity of HDL.
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